相似文献
1
Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups.了解你的邻居：不同的肿瘤微环境对髓母细胞瘤各亚组的免疫治疗靶向策略具有影响。
Oncoimmunology. 2016 Feb 18;5(11):e1144002. doi: 10.1080/2162402X.2016.1144002. eCollection 2016.
2
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.小鼠髓母细胞瘤分子亚型间的差异免疫微环境及对免疫检查点阻断的反应
Clin Cancer Res. 2016 Feb 1;22(3):582-95. doi: 10.1158/1078-0432.CCR-15-0713. Epub 2015 Sep 24.
3
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.鉴定和验证头颈部鳞状细胞癌基于微环境的新型免疫分子亚群：对免疫治疗的影响。
Ann Oncol. 2019 Jan 1;30(1):68-75. doi: 10.1093/annonc/mdy470.
4
Epigenetics and immune cells in medulloblastoma.髓母细胞瘤中的表观遗传学与免疫细胞
Front Genet. 2023 Mar 10;14:1135404. doi: 10.3389/fgene.2023.1135404. eCollection 2023.
5
Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.免疫分析在小儿和成人高级别胶质瘤突变和转录亚群中的作用
Cancer Immunol Res. 2019 Sep;7(9):1401-1411. doi: 10.1158/2326-6066.CIR-18-0939. Epub 2019 Jul 2.
6
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.针对肿瘤微环境克服免疫检查点阻断治疗耐药性。
Immunol Lett. 2020 Apr;220:88-96. doi: 10.1016/j.imlet.2019.03.006. Epub 2019 Mar 15.
7
Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.人白细胞抗原I类抗原加工机制在髓母细胞瘤中的表达及功能分析
Cancer Res. 2007 Jun 1;67(11):5471-8. doi: 10.1158/0008-5472.CAN-06-4735.
8
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.工程化新城疫病毒作为免疫检查点抑制剂和免疫细胞因子瘤内递送的溶瘤载体。
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01677-19.
9
Updates on Management of Adult Medulloblastoma.成人髓母细胞瘤治疗进展。
Curr Treat Options Oncol. 2019 Jun 24;20(8):64. doi: 10.1007/s11864-019-0663-0.
10
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors.已建立的皮下小鼠肿瘤中肿瘤免疫和非免疫微环境的富集与表征
J Vis Exp. 2018 Jun 7(136):57685. doi: 10.3791/57685.
引用本文的文献
1
Characterization of immune microenvironment associated with medulloblastoma metastasis based on explainable machine learning.基于可解释机器学习的髓母细胞瘤转移相关免疫微环境特征分析
Pediatr Investig. 2025 Feb 14;9(1):59-69. doi: 10.1002/ped4.12471. eCollection 2025 Mar.
2
Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review.小儿脑肿瘤微环境的免疫生物学与细胞因子调节：一项范围综述
Cancers (Basel). 2023 Jul 18;15(14):3655. doi: 10.3390/cancers15143655.
3
Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.放疗前患者复发性髓母细胞瘤：诊断与治疗的当前实践
Cancers (Basel). 2021 Dec 28;14(1):126. doi: 10.3390/cancers14010126.
4
Decoding the Roles of Astrocytes and Hedgehog Signaling in Medulloblastoma.解析少突胶质细胞瘤细胞和 Hedgehog 信号在髓母细胞瘤中的作用。
Curr Oncol. 2021 Aug 11;28(4):3058-3070. doi: 10.3390/curroncol28040267.
5
CAR T Cell Therapy for Pediatric Brain Tumors.儿童脑肿瘤的嵌合抗原受体T细胞疗法
Front Oncol. 2020 Aug 12;10:1582. doi: 10.3389/fonc.2020.01582. eCollection 2020.
6
The molecular biology of medulloblastoma metastasis.成神经管细胞瘤转移的分子生物学。
Brain Pathol. 2020 May;30(3):691-702. doi: 10.1111/bpa.12811. Epub 2020 Jan 15.
7
Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics.儿童中枢神经系统胚胎性肿瘤：靶向治疗时代
Bioengineering (Basel). 2018 Sep 23;5(4):78. doi: 10.3390/bioengineering5040078.
8
The evolution of medulloblastoma therapy to personalized medicine.髓母细胞瘤治疗向个性化医疗的演变。
F1000Res. 2017 Apr 13;6:490. doi: 10.12688/f1000research.10859.1. eCollection 2017.
本文引用的文献
1
Vaccination strategies for neuro-oncology.神经肿瘤学的疫苗接种策略。
Neuro Oncol. 2015 Nov;17 Suppl 7(Suppl 7):vii15-vii25. doi: 10.1093/neuonc/nov159.
2
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.小鼠髓母细胞瘤分子亚型间的差异免疫微环境及对免疫检查点阻断的反应
Clin Cancer Res. 2016 Feb 1;22(3):582-95. doi: 10.1158/1078-0432.CCR-15-0713. Epub 2015 Sep 24.
3
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
4
Tumor-associated macrophages in SHH subgroup of medulloblastomas.髓母细胞瘤SHH亚组中的肿瘤相关巨噬细胞
Clin Cancer Res. 2015 Mar 15;21(6):1457-65. doi: 10.1158/1078-0432.CCR-14-1144. Epub 2014 Oct 24.
5
Novel mutations target distinct subgroups of medulloblastoma.新突变靶向不同的髓母细胞瘤亚群。
Nature. 2012 Aug 2;488(7409):43-8. doi: 10.1038/nature11213.
6
The clinical implications of medulloblastoma subgroups.成神经管细胞瘤亚组的临床意义。
Nat Rev Neurol. 2012 May 8;8(6):340-51. doi: 10.1038/nrneurol.2012.78.
7
An animal model of MYC-driven medulloblastoma.一种 MYC 驱动型髓母细胞瘤动物模型。
Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.
8
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.抗程序性死亡-1 单药（MDX-1106）治疗难治性实体瘤的 I 期研究：安全性、临床活性、药效学和免疫相关性。
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
9
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.髓母细胞瘤可由谱系受限的祖细胞或干细胞中patched基因的缺失引发。
Cancer Cell. 2008 Aug 12;14(2):135-45. doi: 10.1016/j.ccr.2008.07.003.
Zotero 插件